A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)
Classical Hodgkin Lymphoma Recurrent · Classical Hodgkin Lymphoma Refractory · Primary Mediastinal Large B-cell Lymphoma Recurrent · Primary Mediastinal Large B-cell Lymphoma Refractory
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 2
- Patients
- 66 (planned)
- Started
- Oct 14, 2024
- Main results expected
- Nov 8, 2028
- Fully finished
- Nov 8, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (ORR) per Lugano Classification Criteria as Assessed by Investigator
Measured over: Up to approximately 48 months
Maximum Concentration (Cmax) of Pembrolizumab After Administration of SC Pembrolizumab Coformulated with Hyaluronidase
Measured over: At designated time points (up to ~6 weeks)
Lowest Plasma Concentration (Ctrough) of Pembrolizumab After Administration of SC Pembrolizumab Coformulated with Hyaluronidase
Measured over: At designated time points (up to ~6 weeks)
Area Under the Concentration-Time Curve of Pembrolizumab After Administration of SC Pembrolizumab Coformulated with Hyaluronidase from Week 0-Week 6 (AUC0-6weeks)
Measured over: At designated time points (up to ~6 weeks)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06504394 · record last updated 2026-02-09 · checked 2026-11-09 15:47 UTC